Financial Contrast: Zomedica (OTC:ZOMDF) vs. Palatin Technologies (PINK:PTNT)

Palatin Technologies (PINK:PTNT) and Zomedica (OTC:ZOMDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Insider and Institutional Ownership

11.5% of Palatin Technologies shares are held by institutional investors. Comparatively, 8.9% of Zomedica shares are held by institutional investors. 7.1% of Palatin Technologies shares are held by company insiders. Comparatively, 5.6% of Zomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Palatin Technologies and Zomedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palatin Technologies	N/A	N/A	-365.57%
Zomedica	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Palatin Technologies and Zomedica, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palatin Technologies	0	0	1	0	3.00
Zomedica	0	0	0	0	0.00

Palatin Technologies currently has a consensus price target of $350.00, indicating a potential upside of 6,150.00%. Given Palatin Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Palatin Technologies is more favorable than Zomedica.

Risk and Volatility

Palatin Technologies has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Zomedica has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Earnings & Valuation

This table compares Palatin Technologies and Zomedica”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palatin Technologies	$4.49 million	32.44	-$29.74 million	($1.55)	-3.61
Zomedica	N/A	N/A	N/A	($0.10)	-1.08

Zomedica has lower revenue, but higher earnings than Palatin Technologies. Palatin Technologies is trading at a lower price-to-earnings ratio than Zomedica, indicating that it is currently the more affordable of the two stocks.

Summary

Palatin Technologies beats Zomedica on 6 of the 10 factors compared between the two stocks.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.